These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28340405)

  • 1. Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions.
    Kodati D; Yellu N
    Pharmacol Rep; 2017 Jun; 69(3):492-496. PubMed ID: 28340405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
    Kodati D; Kotakonda HK; Yellu N
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):573-581. PubMed ID: 27535556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based meta-analysis of furosemide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section.
    Gonçalves PVB; Moreira FL; Benzi JRL; Duarte G; Lanchote VL
    J Clin Pharmacol; 2020 Dec; 60(12):1655-1661. PubMed ID: 32562572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension.
    Shukla M; Ibrahim MMA; Jain M; Jaiswal S; Sharma A; Hanif K; Lal J
    Eur J Pharm Sci; 2017 Nov; 109():253-261. PubMed ID: 28821435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonrelevant Pharmacokinetic Drug-Drug Interaction Between Furosemide and Pindolol Enantiomers in Hypertensive Parturient Women.
    Gonçalves PVB; Moreira FL; Benzi JRL; Cavalli RC; Duarte G; Lanchote VL
    J Clin Pharmacol; 2020 Nov; 60(11):1527-1529. PubMed ID: 32789919
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius).
    Ali BH; Wong YC; Alhadrami GA; Charles BG; Bashir AK
    Res Vet Sci; 1998; 64(1):69-72. PubMed ID: 9557809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    Yoshihara K; Gao Y; Shiga H; Wada DR; Hisaoka M
    Clin Pharmacokinet; 2005; 44(12):1329-42. PubMed ID: 16372830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus.
    Park JH; Lee WI; Yoon WH; Park YD; Lee JS; Lee MG
    Biopharm Drug Dispos; 1998 Sep; 19(6):357-64. PubMed ID: 9737816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.
    Wakelkamp M; Alván G; Gabrielsson J; Paintaud G
    Clin Pharmacol Ther; 1996 Jul; 60(1):75-88. PubMed ID: 8689815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure.
    Carlton LD; Patterson JH; Mattson CN; Schmith VD
    J Clin Pharmacol; 1996 Mar; 36(3):257-64. PubMed ID: 8690820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
    Paterna S; Di Pasquale P; Parrinello G; Amato P; Cardinale A; Follone G; Giubilato A; Licata G
    Eur J Heart Fail; 2000 Sep; 2(3):305-13. PubMed ID: 10938493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Optimal way of administration of high dose intravenous furosemide - continuous infusion or bolus?].
    Gallusová J; Halačová M; Cerný D
    Vnitr Lek; 2014 Oct; 60(10):885-92. PubMed ID: 25382011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
    Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
    Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Both in vitro and in vivo Kinetics by SLNs Induced Transdermal System of Furosemide: A Novel Approach.
    Mannam R; Yallamalli IM
    Recent Pat Drug Deliv Formul; 2017; 11(3):187-197. PubMed ID: 29189185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.